Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue them or never receive a prescription due to ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue them or never receive a prescription due to ...

Our Lady of Lourdes Regional Medical Center is embracing cutting-edge technology to transform how heart conditions are ...

For people with atrial fibrillation (Afib), investigational abelacimab proved to be a potent dual factor XI/XIa inhibitor with much lower safety risks compared with a direct oral anticoagulant (DOAC), ...

Boston Scientific outperforms competitors with strong growth in atrial fibrillation devices and recent acquisitions. Learn ...

On the second Wednesday of the month at 10 a.m., witness a special showcase of local spinners sharing how they craft fibers ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue ...

Clinically significant reductions in bleeding underscore abelacimab’s strong potential to address an unmet need for patients ...

The results will support the company’s application for expanded labeling of its popular Farapulse pulsed field ablation ...

A New Pacemaker Algorithm for the Treatment of Atrial Fibrillation: Results of the Atrial Dynamic Overdrive Pacing Trial (ADOPT) Electrophysiologic Characteristics of the Spontaneous Onset and ...